To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
PPD to Discover Biomarkers for PDL BioPharma
PPD, Inc. has announced it has signed an agreement by which it will perform comprehensive molecular profiling to discover biomarkers for PDL BioPharma, Inc.
Under the terms of the agreement, PPD's biomarker discovery sciences group will examine specified sample sets utilizing DeepLook™ analysis, its proprietary integrated platform for mass spectrometry-based discovery of biomarkers.
"Identification and implementation of biomarkers can accelerate clinical trials by improving diagnosis, patient selection, and monitoring of disease progression and therapeutic response," said Howard Schulman, vice president of PPD's biomarker discovery sciences.
"We look forward to working with PDL BioPharma to develop biomarkers for its clinical development programs."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
